Unit of Urology, Department of Surgery, AULSS6 Euganea, Piove di Sacco, Padua, Italy -
Unit of Urology, Department of Surgery, AULSS6 Euganea, Piove di Sacco, Padua, Italy.
Panminerva Med. 2022 Sep;64(3):337-343. doi: 10.23736/S0031-0808.21.04507-9. Epub 2021 Dec 3.
Emerging evidence supports the hypothesis that metabolic syndrome is associated with cancer pathogenesis. In particular regarding prostate cancer, observational studies from various settings report different results. This systematic review and meta-analysis aimed to provide a quantitative estimate of the association between metabolic syndrome in prostate cancer, in particular Gleason Score >6, accounting for different study designs.
Systematic research of available literature in English language until 2020 was conducted through in Embase, Medline, Cochrane Library and NIH Registry of Clinical Trials. For each study, information regarding the study design, the population, the definition of metabolic syndrome, data relating to prostate cancer were collected, the association between MetS and outcome of interest was determined by calculating the generic inverse variance with random effects method.
In the final sample 19 studies were included with total of 114,329 patients, 29.4% met the criteria for metabolic syndrome. We report a significant association between metabolic syndrome and prostate cancer in cross-sectional studies (OR=1.30; 95% CI: 1.13-1.49) and for patients with clinically significant prostate cancer (OR=1.56; 95% CI: 1.23-1.99). Association between metabolic syndrome and prostate cancer combining all studies, in cohort studies and case-control studies was not significant.
Growing evidence support the association between metabolic syndrome and prostate cancer, bias derived from observational studies might conceal further findings.
越来越多的证据支持代谢综合征与癌症发病机制相关的假说。特别是在前列腺癌方面，来自不同环境的观察性研究报告了不同的结果。本系统评价和荟萃分析旨在提供代谢综合征与前列腺癌（特别是 Gleason 评分>6）之间关联的定量估计，同时考虑到不同的研究设计。
通过 Embase、Medline、Cochrane 图书馆和 NIH 临床试验注册处，以英文进行了现有文献的系统研究，直至 2020 年。对于每项研究，我们收集了研究设计、人群、代谢综合征定义、与前列腺癌相关的数据等信息，通过计算随机效应方法的通用倒数方差，确定代谢综合征与研究结果之间的关联。
在最终的样本中，有 19 项研究纳入了总共 114329 名患者，其中 29.4%符合代谢综合征的标准。我们报告了代谢综合征与横断面研究中前列腺癌之间的显著关联（OR=1.30；95% CI：1.13-1.49）和临床上显著的前列腺癌患者（OR=1.56；95% CI：1.23-1.99）之间的关联。对所有研究进行合并分析，以及在队列研究和病例对照研究中，代谢综合征与前列腺癌之间的关联没有统计学意义。
越来越多的证据支持代谢综合征与前列腺癌之间的关联，但来自观察性研究的偏倚可能掩盖了进一步的发现。
